C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
Background and Rationale
This comprehensive clinical study addresses the enigmatic phenotypic divergence observed in C9orf72 hexanucleotide repeat expansion carriers, who can develop either amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) despite sharing identical genetic mutations. The C9orf72 repeat expansion is the most common genetic cause of both diseases, yet the molecular mechanisms determining phenotypic expression remain poorly understood. This study will employ cutting-edge multi-omics approaches including whole transcriptome sequencing, proteomic profiling, and advanced neuroimaging to identify distinct molecular signatures that predispose to motor neuron versus cortical degeneration patterns.
The research design incorporates longitudinal assessment of C9orf72 carriers across the disease spectrum, from presymptomatic through established ALS or FTD phenotypes. Key investigations include RNA sequencing to identify differential expression patterns, particularly focusing on repeat-associated non-ATG translation products and RNA foci formation. Advanced diffusion tensor imaging and functional connectivity MRI will map distinct patterns of white matter degradation and network dysfunction. Cerebrospinal fluid analysis will quantify neurofilament light chain, TDP-43, and other neurodegeneration biomarkers. This integrated approach aims to identify predictive biomarkers that could enable early intervention and personalized therapeutic strategies for C9orf72 carriers based on their anticipated phenotypic trajectory.
This experiment directly tests predictions arising from the following hypotheses:
- Stress Granule Phase Separation Modulators
- RNA Granule Nucleation Site Modulation
- Phase-Separated Organelle Targeting
- Low Complexity Domain Cross-Linking Inhibition
Experimental Protocol
Phase 1: Patient Recruitment and Phenotyping (Months 1-6)• Recruit 200 C9orf72 expansion carriers (100 ALS, 100 FTD) through neurology clinics
• Perform comprehensive neurological assessments using ALS Functional Rating Scale-Revised (ALSFRS-R) and Frontotemporal Dementia Rating Scale (FRS)
• Collect detailed family history and conduct cognitive testing (Montreal Cognitive Assessment, Addenbrooke's Cognitive Examination)
• Obtain informed consent for biosampling and genetic analysis
• Recruit 100 age-matched healthy controls
Phase 2: Biospecimen Collection and Processing (Months 2-8)
• Collect CSF (15mL), plasma (20mL), and serum (10mL) from all participants
• Extract peripheral blood mononuclear cells (PBMCs) and establish lymphoblastoid cell lines
• Perform immediate processing and aliquoting at -80°C storage
• Generate induced pluripotent stem cells (iPSCs) from 50 representative patients (25 ALS, 25 FTD)
• Differentiate iPSCs into motor neurons and cortical neurons using established protocols
Phase 3: Molecular Analysis (Months 6-18)
• Quantify C9orf72 repeat expansions using repeat-primed PCR and Southern blotting
• Measure RNA foci formation using fluorescent in situ hybridization (FISH) in patient-derived neurons
• Analyze dipeptide repeat protein (DPR) accumulation via immunofluorescence and Western blotting
• Perform RNA sequencing on patient-derived neurons to identify differential splicing patterns
• Conduct proteomics analysis using mass spectrometry on CSF and neuronal lysates
Phase 4: Functional Characterization (Months 12-24)
• Assess neuronal viability using MTT assays and live/dead staining at multiple timepoints
• Measure axonal transport defects using mitochondrial trafficking assays in motor neurons
• Evaluate synaptic function through electrophysiology recordings and calcium imaging
• Analyze stress granule dynamics and nucleocytoplasmic transport using time-lapse microscopy
• Perform transcriptional profiling to identify disease-specific gene expression signatures
Phase 5: Biomarker Validation (Months 18-30)
• Validate candidate biomarkers in independent cohort of 150 patients (75 ALS, 75 FTD)
• Develop and optimize ELISA assays for top 5 discriminatory proteins
• Establish reference ranges and cutoff values using ROC curve analysis
• Correlate biomarker levels with disease severity and progression rates
• Perform longitudinal sampling every 6 months to assess biomarker dynamics
Expected Outcomes
C9orf72 repeat expansion length correlation: ALS patients will show significantly longer repeat expansions (>500 repeats) compared to FTD patients (200-500 repeats) with correlation coefficient r >0.6 (p<0.001)
Differential DPR protein accumulation: poly-GP and poly-GR levels will be 3-fold higher in ALS motor neurons compared to FTD cortical neurons, while poly-PR will show 2-fold higher accumulation in FTD neurons (p<0.01 for all comparisons)
Disease-specific RNA foci distribution: ALS patients will demonstrate predominantly cytoplasmic RNA foci (>70% cytoplasmic vs <30% nuclear), while FTD patients will show primarily nuclear foci (>60% nuclear vs <40% cytoplasmic)
Distinct transcriptomic signatures: RNA-seq analysis will identify >500 differentially expressed genes between ALS and FTD neurons (FDR<0.05, fold-change >1.5), with ALS showing enrichment in axonal transport pathways and FTD in synaptic signaling
CSF biomarker panel performance: A 5-protein biomarker panel will achieve AUC >0.85 for discriminating ALS from FTD phenotypes, with sensitivity >80% and specificity >85%
Functional divergence in cellular phenotypes: ALS neurons will show 40% reduction in axonal transport velocity compared to controls, while FTD neurons will demonstrate 50% decrease in dendritic spine density (both p<0.001)Success Criteria
•
Statistical power achievement: Complete recruitment of minimum 160 C9orf72 carriers (80 ALS, 80 FTD) to achieve 80% power for detecting medium effect sizes (Cohen's d=0.5)
• Biomarker discrimination performance: Identify at least 3 biomarkers with individual AUC >0.75 and combined panel AUC >0.85 for ALS vs FTD classification
• Molecular mechanism validation: Demonstrate statistically significant differences (p<0.01) in at least 4 of 6 key molecular readouts: repeat length, DPR proteins, RNA foci, gene expression, protein aggregation, and cellular dysfunction
• Reproducibility confirmation: Validate top findings in independent validation cohort with effect sizes within 20% of discovery cohort results and maintained statistical significance
• Clinical correlation establishment: Achieve significant correlations (|r|>0.4, p<0.05) between molecular biomarkers and clinical severity scores (ALSFRS-R for ALS, FRS for FTD)
• Data quality standards: Maintain >95% sample quality metrics, <10% missing data across primary endpoints, and successful iPSC differentiation efficiency >70% for neuronal cultures